> 首页 > 产品 > 一抗 > 精选抗体 > Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (conatumumab)

Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (conatumumab)

Recombinant Antibody

Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (conatumumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (conatumumab) is 98.4%, determined by SEC-HPLC.
Immobilized Human TNFRSF10B/TRAILR2/CD262, Fc Tag at 2 ug/mL can bind Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody (conatumumab), The EC50 is 0.03101 ug/mL.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	O14763
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	47878 Da

Additional Information
Target/Specificity	TNFRSF10B / TRAILR2 / CD262
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Protein Information
Name	TNFRSF10B
Synonyms	DR5, KILLER, TRAILR2, TRICK2, ZTNFR9
Function	Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed:10549288). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.
Cellular Location	Membrane; Single-pass type I membrane protein.
Tissue Location	Widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines such as HeLaS3, K-562, HL-60, SW480, A-549 and G-361; highly expressed in heart, peripheral blood lymphocytes, liver, pancreas, spleen, thymus, prostate, ovary, uterus, placenta, testis, esophagus, stomach and throughout the intestinal tract; not detectable in brain

Research Areas

Application Protocols

Provided below are standard protocols that you may find useful for product applications.

Western Blot Protocol

Blocking Peptides Protocol

Dot Blot Protocol

Immunohistochemistry Protocol

Immunofluorescence Protocol

Immunoprecipitation Protocol

Flow Cytomety Protocol

Cell Culture Protocol